Figure 4.

Schematic of EGFR and mTOR signaling network, and signaling mediator effects associated with rapamycin and/or EKI-785 treatments. A notation of an “E” or “R,” in association with a signaling pathway, indicates where the pathway is blocked by EKI-785 or rapamycin, respectively.